Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor‐positive advanced breast cancer

Taselisib is a potent and selective phosphatidylinositide 3‐kinase (PI3K) inhibitor. The present article reports the first study of taselisib administration in Japanese patients. The aim of this 2‐stage, phase I, multicenter, open‐label, dose‐escalation study was to evaluate the safety, pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Kenji, Kodaira, Makoto, Shimizu, Chikako, Yonemori, Kan, Yunokawa, Mayu, Shimomura, Akihiko, Kobayashi, Takayuki, Nakano, Kenji, Tomomatsu, Junichi, Ito, Yoshinori, Tanaka, Jun, Kuriki, Hiroshi, Gu, Zhaodi, Takahashi, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980117/
https://www.ncbi.nlm.nih.gov/pubmed/29500843
http://dx.doi.org/10.1111/cas.13561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980117/
https://www.ncbi.nlm.nih.gov/pubmed/29500843
http://dx.doi.org/10.1111/cas.13561

Ejemplares similares